Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma

PURPOSE Low-grade serous carcinoma (LGSC) is a rare type of ovarian cancer, which commonly arises from serous borderline tumor (SBT) and is characterized by frequent activating mutations in the mitogen-activated protein kinase pathway, including BRAF. The BRAFV600E mutation is associated with improved prognosis in SBT and LGSC, and responses to BRAF inhibitor therapy have been reported. We sought to characterize the clinicopathologic and molecular features of BRAF-driven tubo-ovarian and primary peritoneal serous tumors. METHODS Retrospective analysis of our institutional cohort of SBTs (n = 22), LGSCs (n = 119) and high-grade serous carcinomas (HGSCs, n = 1,290) subjected to targeted massively parallel sequencing was performed to identify cases with BRAF genetic alterations. Putative BRAF rearrangements were confirmed using targeted RNA sequencing and/or fluorescence in situ hybridization (FISH). BRAFV600E oncoprotein expression was assessed by immunohistochemistry on selected cases. RESULTS BRAF somatic genetic alterations were identified in 29 of 1,431 (2%) serous tumors and included mutations (n = 24), gene rearrangements (n = 3), and amplification (n = 2). BRAF mutations were more frequent in SBTs (7 of 22; 32%) compared with LGSCs (11 of 119; 9%, P = .009) and HGSCs (6 of 1,290; 0.5%; P < .0001, SBT/LGSC v HGSC). The BRAFV600E hotspot mutation was most common (n = 16); however, other BRAF driver mutations were also detected (n = 8). BRAF mutations were often clonal or truncal in SBTs and LGSCs, but subclonal in most HGSCs. Pathogenic BRAF gene fusions were identified in LGSCs (n = 2) and HGSC (n = 1) and involved distinct fusion partners (AGK, MKRN1, and AGAP3). Three patients with BRAF-mutant LGSC were treated with targeted mitogen-activated protein kinase inhibitors, one of whom was maintained on therapy for over 3 years with clinical benefit. CONCLUSION Recognition of BRAF alterations beyond V600E mutation in LGSC may have clinical implications for appropriate targeted therapy selection. Novel BRAF non-V600E mutations and gene re-arrangements in ovarian serous carcinoma

[1]  J. Reis-Filho,et al.  Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes , 2020, Modern Pathology.

[2]  B. Monk,et al.  MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Reis-Filho,et al.  Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary , 2020, Modern Pathology.

[4]  I. Shih,et al.  BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma , 2019, Oncotarget.

[5]  L. Cope,et al.  Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma , 2019, The American journal of surgical pathology.

[6]  Robert L. Judson,et al.  Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses. , 2019, Cell reports.

[7]  H. Gabra,et al.  A Randomized Phase II/III Study to Assess the Efficacy of Trametinib in Patients with Recurrent or Progressive Low-Grade Serous Ovarian or Peritoneal Cancer , 2019, Gynecologic Oncology.

[8]  J. Eshleman,et al.  Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing , 2019, BMC Cancer.

[9]  C. Longui,et al.  AGK‐BRAF is associated with distant metastasis and younger age in pediatric papillary thyroid carcinoma , 2019, Pediatric blood & cancer.

[10]  M. Ladanyi,et al.  Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma , 2018, Modern Pathology.

[11]  A. Iafrate,et al.  Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer , 2018, Clinical Cancer Research.

[12]  G. Turashvili,et al.  BRAFV600E mutations and immunohistochemical expression of VE1 protein in low‐grade serous neoplasms of the ovary , 2018, Histopathology.

[13]  D. Etemadmoghadam,et al.  BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. , 2018, JCO precision oncology.

[14]  P. Stephens,et al.  BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy , 2018, Pigment cell & melanoma research.

[15]  P. Siegel,et al.  Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations , 2018, Oncogene.

[16]  E. White,et al.  BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma , 2017, Clinical Cancer Research.

[17]  V. Seshan,et al.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.

[18]  A. Reuss,et al.  Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. , 2016, Gynecologic oncology.

[19]  P. Stephens,et al.  Identification of BRAF Kinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy. , 2016, JAMA oncology.

[20]  H. Blons,et al.  Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation , 2015, Investigational New Drugs.

[21]  Kylie L. Gorringe,et al.  Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes , 2015, Oncotarget.

[22]  Kai Wang,et al.  The distribution of BRAF gene fusions in solid tumors and response to targeted therapy , 2015, International journal of cancer.

[23]  N. Socci,et al.  Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Blay,et al.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.

[25]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[26]  I. Shih,et al.  BRAF Mutation Is Associated With a Specific Cell Type With Features Suggestive of Senescence in Ovarian Serous Borderline (Atypical Proliferative) Tumors , 2014, The American journal of surgical pathology.

[27]  Alexia Iasonos,et al.  BRAF Mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer , 2013, Cancer.

[28]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[29]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[30]  S. Mok,et al.  BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. , 2010, The American journal of pathology.

[31]  I. Shih,et al.  Ovarian Low-grade and High-grade Serous Carcinoma: Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems , 2009, Advances in anatomic pathology.

[32]  D. Bodurka,et al.  Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. , 2008, Gynecologic oncology.

[33]  Chung-Liang Ho,et al.  Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors , 2004, Cancer Research.

[34]  I. Shih,et al.  Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.

[35]  P. Stephens,et al.  A FISH assay efficiently screens for BRAF gene rearrangements in pancreatic acinar-type neoplasms , 2018, Modern Pathology.

[36]  Any Cheung,et al.  WHO Classification of Tumours 5th Edition , 2018 .

[37]  N. Socci,et al.  Accelerating Discovery of Functional Mutant Alleles in Cancer. , 2018, Cancer discovery.